Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate


Vaxcyte Inc PCVX priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively.

  • Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering.
  • The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $100.0 million.
  • The underwriters have an option to purchase additional 750,000 shares.
  • The offering will close on January 18, 2022.
  • BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers. 
  • Cantor is acting as lead manager for the offering. Needham & Company is acting as co-manager for the offering.
  • Last week, the FDA signed off Vaxcyte's lead Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate.
  • Vaxcyte expects to initiate the Phase 1/2 clinical proof-of-concept study in adults in Q1 of 2022 and announce topline immunogenicity results by the end of the year.
  • Price Action: PCVX shares are down 2.27% at $21.50 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapMoversTrading IdeasGeneralBriefsPhase 1 TrialPhase 2 TrialPneumococcal Disease
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!